2013 Q3 Form 10-Q Financial Statement

#000144530513002083 Filed on August 09, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $3.943M $6.974M $22.91M
YoY Change -85.03% -69.56% -12.07%
Cost Of Revenue $494.0K $3.631M $5.829M
YoY Change -92.28% -37.71% -17.97%
Gross Profit $3.449M $3.343M $17.08M
YoY Change -82.71% -80.43% -9.86%
Gross Profit Margin 87.47% 47.94% 74.56%
Selling, General & Admin $5.832M $7.169M $6.789M
YoY Change -26.26% 5.6% -26.81%
% of Gross Profit 169.09% 214.45% 39.75%
Research & Development $6.831M $8.624M $15.65M
YoY Change -51.86% -44.89% 4.58%
% of Gross Profit 198.06% 257.97% 91.63%
Depreciation & Amortization $2.610M $2.590M $3.230M
YoY Change -16.88% -19.81% 16.19%
% of Gross Profit 75.67% 77.48% 18.91%
Operating Expenses $13.16M $19.42M $28.27M
YoY Change -53.83% -31.29% -9.82%
Operating Profit -$9.214M -$12.45M -$5.359M
YoY Change 327.37% 132.32% -56.78%
Interest Expense $10.00K $20.00K $70.00K
YoY Change -83.33% -71.43% 0.0%
% of Operating Profit
Other Income/Expense, Net $22.00K $183.0K $157.0K
YoY Change -51.11% 16.56% 685.0%
Pretax Income -$9.227M -$12.62M -$5.442M
YoY Change 331.17% 131.84% 4.55%
Income Tax $35.00K -$12.00K $77.00K
% Of Pretax Income
Net Earnings -$9.262M -$12.61M -$5.519M
YoY Change 301.13% 128.39% 9.5%
Net Earnings / Revenue -234.9% -180.74% -24.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$243.0K -$331.3K -$152.1K
COMMON SHARES
Basic Shares Outstanding 38.09M shares 38.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.92M $37.90M $51.40M
YoY Change -40.63% -26.26% 10.06%
Cash & Equivalents $26.91M $32.39M $16.69M
Short-Term Investments $3.009M $5.512M $34.70M
Other Short-Term Assets $1.900M $2.300M $5.100M
YoY Change -63.46% -54.9% 112.5%
Inventory $2.101M $1.332M $4.200M
Prepaid Expenses
Receivables $2.688M $1.591M $8.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $36.64M $43.11M $68.80M
YoY Change -51.01% -37.34% 6.67%
LONG-TERM ASSETS
Property, Plant & Equipment $13.81M $15.52M $22.10M
YoY Change -30.61% -29.77% 2.31%
Goodwill $3.241M $3.241M
YoY Change
Intangibles $10.40M $11.25M
YoY Change
Long-Term Investments $1.100M $1.000M $6.100M
YoY Change -69.44% -83.61% -76.36%
Other Assets $361.0K $363.0K $2.800M
YoY Change -90.24% -87.04% 3.7%
Total Long-Term Assets $29.79M $32.50M $48.90M
YoY Change -32.6% -33.54% -31.7%
TOTAL ASSETS
Total Short-Term Assets $36.64M $43.11M $68.80M
Total Long-Term Assets $29.79M $32.50M $48.90M
Total Assets $66.44M $75.61M $117.7M
YoY Change -44.17% -35.76% -13.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.490M $1.545M $4.300M
YoY Change -76.35% -64.07% -44.16%
Accrued Expenses $2.140M $3.900M $11.70M
YoY Change -82.31% -66.67% -5.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.218M $11.15M $19.60M
YoY Change -55.47% -43.14% -20.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.183M $3.783M $5.500M
YoY Change -2.21% -31.22% 17.02%
Total Long-Term Liabilities $5.183M $3.783M $5.500M
YoY Change -2.21% -31.22% 17.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.218M $11.15M $19.60M
Total Long-Term Liabilities $5.183M $3.783M $5.500M
Total Liabilities $14.40M $14.93M $25.20M
YoY Change -44.61% -40.76% -13.99%
SHAREHOLDERS EQUITY
Retained Earnings -$247.0M -$237.8M
YoY Change
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.87M $59.47M $92.50M
YoY Change
Total Liabilities & Shareholders Equity $66.44M $75.61M $117.7M
YoY Change -44.17% -35.76% -13.52%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$9.262M -$12.61M -$5.519M
YoY Change 301.13% 128.39% 9.5%
Depreciation, Depletion And Amortization $2.610M $2.590M $3.230M
YoY Change -16.88% -19.81% 16.19%
Cash From Operating Activities -$8.530M -$7.070M -$3.880M
YoY Change 120.41% 82.22% -49.15%
INVESTING ACTIVITIES
Capital Expenditures $190.0K -$590.0K -$440.0K
YoY Change -337.5% 34.09% -86.67%
Acquisitions
YoY Change
Other Investing Activities $2.850M $8.810M -$5.780M
YoY Change -76.68% -252.42% -47.69%
Cash From Investing Activities $3.040M $8.220M -$6.220M
YoY Change -74.96% -232.15% -56.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 20.00K 200.0K
YoY Change -98.33% -90.0% -77.78%
NET CHANGE
Cash From Operating Activities -8.530M -7.070M -3.880M
Cash From Investing Activities 3.040M 8.220M -6.220M
Cash From Financing Activities 10.00K 20.00K 200.0K
Net Change In Cash -5.480M 1.170M -9.900M
YoY Change -161.78% -111.82% -53.04%
FREE CASH FLOW
Cash From Operating Activities -$8.530M -$7.070M -$3.880M
Capital Expenditures $190.0K -$590.0K -$440.0K
Free Cash Flow -$8.720M -$6.480M -$3.440M
YoY Change 130.08% 88.37% -20.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1545000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3654000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7545000 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1591000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-377000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
48000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6948000 USD
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3541000 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3900000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34172000 USD
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37084000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-136000 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
106000 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
297144000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
294128000 USD
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
150000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
150000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1806000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1687000 USD
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9365000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6898000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9365000 shares
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6898000 shares
CY2013Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
300000 USD
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
15000 USD
CY2012Q4 us-gaap Assets
Assets
99965000 USD
CY2013Q2 us-gaap Assets
Assets
75606000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
43107000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
59769000 USD
CY2013Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
30090000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41873000 USD
CY2013Q2 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
30550000 USD
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
41936000 USD
CY2013Q2 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
0 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
0 USD
CY2013Q2 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
460000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
63000 USD
CY2013Q2 us-gaap Cash
Cash
8400000 USD
CY2012Q4 us-gaap Cash
Cash
7200000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32392000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25762000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16693000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4544000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9069000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
389000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
87000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2365000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2186000 USD
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1299000 USD
CY2013Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1207000 USD
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
184895 shares
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable and restricted cash. Cash and cash equivalents, marketable securities and restricted cash are invested through banks and other financial institutions in the United States, as well as in other foreign countries. Such deposits may be in excess of insured limits.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's top </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">73%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;"> of our total revenues for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;">. Accounts receivable balances for the top </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">70%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">84%</font><font style="font-family:inherit;font-size:10pt;"> of total balances as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk with respect to accounts receivable exists to the extent of amounts presented in the condensed consolidated financial statements. The Company estimates an allowance for doubtful accounts through specific identification of potentially uncollectible accounts receivable based on an analysis of its accounts receivable aging. Uncollectible accounts receivable are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from its estimates and could be material to its consolidated financial position, results of operations, and cash flows.</font></div></div>
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5829000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
18471000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9296000 USD
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
3631000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
164000 USD
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3335000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3495000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-77000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
274000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-141000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-109000 USD
CY2013Q2 us-gaap Goodwill
Goodwill
3241000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5442000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12617000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12735000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-22305000 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-12000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6051000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2108000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5954000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10793000 USD
CY2013Q2 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
600000 USD
CY2013Q2 us-gaap Marketable Securities
MarketableSecurities
5512000 USD
CY2012Q4 us-gaap Marketable Securities
MarketableSecurities
13524000 USD
CY2013Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1017000 USD
CY2012Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3623000 USD
CY2013Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
24000000 USD
CY2012Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
24800000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-234000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-160000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2596000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-287000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
30000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3209000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
798000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
409000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
38000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2799000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3116000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-400000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12934000 USD
CY2013Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11247000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
662000 USD
CY2013Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
719000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
1332000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
1302000 USD
CY2013Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
458000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
588000 USD
CY2013Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
155000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
52000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
149000 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
16000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
43000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99965000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75606000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16283000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11145000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Codexis, Inc. (the "Company") was incorporated in the state of Delaware in January 2002. The Company engineers enzymes for pharmaceutical, biofuel and chemical production. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. There are currently over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> pharmaceutical firms using its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also continues to develop its CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes to convert non-food plant material, which the Company calls cellulosic biomass, into affordable sugars, which can then be converted into renewable fuels and chemicals. The Company is also developing its own manufacturing process for CodeXol</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, which are bio-based chemicals. Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents. The Company is seeking collaboration partners to assist it with the development and commercialization of CodeXyme</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes and CodeXol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, and the Company is also exploring other strategic options with respect to these products and technologies. On July 30, 2013, the Company received a notice (the "Dyadic notice") from Dyadic International, Inc. (&#8220;Dyadic&#8221;) asserting that Dyadic believed the Company to be in breach of the parties' November 14, 2008 license agreement (the "Dyadic license agreement") and that Dyadic would terminate the Dyadic license agreement unless the Company cured such breach within </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days of notice. The Company licenses Dyadic's C-1 based proprietary fungal expression technology from Dyadic under the Dyadic license agreement and uses the strain to engineer enzymes that are used in the Company's CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes. The Company's receipt of the Dyadic notice may interfere with its ability to find a collaboration partner for its CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">cellulase enzyme program and the Company's strategic options in respect of this program may be limited until the matter is resolved. For a further discussion of the Dyadic notice and the potential impact the Dyadic notice and the termination of the license agreement would have on Codexis and its businesses, please see the Note 13 for subsequent events.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assists customers in discovering or enhancing enzymes variants by applying its CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once the Company identifies potentially beneficial mutations, it tests combinations of these mutations until it has created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows the Company to make continuous, efficient improvements to the performance of its enzymes. </font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these Notes to condensed consolidated financial statements, the &#8220;Company&#8221; refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
287000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
281000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6228000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10668000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3292000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10560000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-12605000 USD
CY2013Q2 us-gaap Noncurrent Assets
NoncurrentAssets
27131000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reporting_unit
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
28268000 USD
us-gaap Operating Expenses
OperatingExpenses
40535000 USD
us-gaap Operating Expenses
OperatingExpenses
66654000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
19424000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12450000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12609000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5359000 USD
CY2012Q4 us-gaap Noncurrent Assets
NoncurrentAssets
31821000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13009000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22228000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5519000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22080000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
18930000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1438000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2677000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3047000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3031000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2947000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5790000 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
363000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2237000 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
50000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-471000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
242000 USD
CY2012Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-337000 USD
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
32000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
155000 USD
CY2012Q2 us-gaap Other Expenses
OtherExpenses
157000 USD
us-gaap Other Expenses
OtherExpenses
275000 USD
us-gaap Other Expenses
OtherExpenses
268000 USD
CY2013Q2 us-gaap Other Expenses
OtherExpenses
183000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3943000 USD
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3783000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19141000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2551000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
641000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2280000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5395000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4964000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10909000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
281000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
287000 USD
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52559000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50794000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16650000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15520000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
242000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
30480000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
4370000 USD
CY2012Q2 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
15868000 USD
CY2013Q2 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
2026000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8624000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15946000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31999000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15650000 USD
CY2013Q2 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1111000 USD
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
1511000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237783000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215556000 USD
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2012Q2 us-gaap Revenue From Grants
RevenueFromGrants
259000 USD
us-gaap Revenue From Grants
RevenueFromGrants
0 USD
us-gaap Revenue From Grants
RevenueFromGrants
1616000 USD
us-gaap Revenues
Revenues
54045000 USD
CY2012Q2 us-gaap Revenues
Revenues
22909000 USD
us-gaap Revenues
Revenues
18455000 USD
CY2013Q2 us-gaap Revenues
Revenues
6974000 USD
CY2013Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
4948000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
14085000 USD
CY2012Q2 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
6782000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
21949000 USD
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1907000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15293000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16184000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
78440000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
59471000 USD
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1262000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7169000 USD
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6789000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2735000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3077000 USD
CY2012Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-337000 USD
CY2013Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
50000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-636000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's management regularly assesses these estimates which primarily affect revenue recognition, the valuation of marketable securities and accounts receivable, intangible assets, goodwill arising out of business acquisitions, inventories, accrued liabilities, common stock, and stock options and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38060000 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36296000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37951000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36177000 shares
cdxs Classof Warrantor Right Exercise Priceof Warrantsor Rights Expired
ClassofWarrantorRightExercisePriceofWarrantsorRightsExpired
5.96
cdxs Comprehensive Loss
ComprehensiveLoss
-21986000 USD
cdxs Comprehensive Loss
ComprehensiveLoss
-13480000 USD
CY2013Q2 cdxs Comprehensive Loss
ComprehensiveLoss
-12555000 USD
CY2012Q2 cdxs Comprehensive Loss
ComprehensiveLoss
-5856000 USD
CY2011 cdxs Contingent Revenue From Grant
ContingentRevenueFromGrant
500000 USD
CY2012Q2 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
165000 USD
CY2013Q2 cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
0 USD
cdxs Marketable Securities Included In Non Current Asset
MarketableSecuritiesIncludedInNonCurrentAsset
P1Y
cdxs Maturity Date Of Highly Liquid Investments
MaturityDateOfHighlyLiquidInvestments
P3M
cdxs Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
0 USD
cdxs Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
1912000 USD
CY2012Q4 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 security
CY2013Q2 cdxs Number Of Marketable Securities
NumberOfMarketableSecurities
0 Securities
cdxs Number Of Pharmaceutical Firms Using Technology
NumberOfPharmaceuticalFirmsUsingTechnology
50 Entity
cdxs Number Revenue Recognition Criteria
NumberRevenueRecognitionCriteria
4 Criteria
cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
10500000 USD
cdxs Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0 USD
CY2012Q4 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
16622000 USD
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001200375
CY2013Q2 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
15475000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38088637 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
CODEXIS INC

Files In Submission

Name View Source Status
0001445305-13-002083-index-headers.html Edgar Link pending
0001445305-13-002083-index.html Edgar Link pending
0001445305-13-002083.txt Edgar Link pending
0001445305-13-002083-xbrl.zip Edgar Link pending
cdxs-20130630.xml Edgar Link completed
cdxs-20130630.xsd Edgar Link pending
cdxs-20130630_cal.xml Edgar Link unprocessable
cdxs-20130630_def.xml Edgar Link unprocessable
cdxs-20130630_lab.xml Edgar Link unprocessable
cdxs-20130630_pre.xml Edgar Link unprocessable
cdxs_20130630x10q.htm Edgar Link pending
cdxs_20130630xex101.htm Edgar Link pending
cdxs_20130630xex311.htm Edgar Link pending
cdxs_20130630xex312.htm Edgar Link pending
cdxs_20130630xex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending